Dementia and Alzheimer Disease

A pair of lead neurologists at Baptist Health South Florida provided commentary on some of the promising developments expected to emerge in neurology over the coming months.

Total healthcare costs were 14% higher for patients with potentially inappropriate medication use in the Alzheimer-insomnia cohort, with significant contributions from inpatient care, ambulatory care, and pharmacy costs.

Here's some of what is coming soon to NeurologyLive® this week.

Also known as SNK01, the novel NK cell manufacturing technology enables large-scale ex vivo production and expansion of NK cells.

Monthly cycles of low-dose IL-2, or COYA 301, resulted in statistically significant decreases in proinflammatory biomarkers and increases in anti-inflammatory cytokine IL-4 vs placebo.

Here's some of what is coming soon to NeurologyLive® this week.

The group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.

Panelists explore the challenges and opportunities for women in neurology, offering practical advice for young professionals navigating the field.

In this episode, women neurologists share their personal experiences navigating challenges in neurology, offering insights into mentorship, work-life balance, and career advancement.

Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive® team.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

Deborah Benzil, MD, FAAS, vice chair of neurosurgery at Cleveland Clinic's Center for Spine Health, shared her extraordinary journey of resilience, from overcoming repeated rejections to becoming a trailblazer for women in neurosurgery, and reflects on the progress made and the challenges that remain.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

Here's some of what is coming soon to NeurologyLive® this week.

The chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]

Neal K. Shah talked about an artificial intelligence innovation that can be used to fight denied health insurance claims, thus improving revenue cycle management for physicians' practices and the patient experience.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 31, 2024.

The chief of neuroinfectious diseases and global neurology at Northwestern Medicine talked about a relatively new autoimmune condition, marked by mitochondrial dysfunction. [WATCH TIME: 2 minutes]

Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won’t want to miss.

Here's some of what is coming soon to NeurologyLive® this week.

Once-monthly maintenance dosing with LEQEMBI offers convenience for patients and caregivers while slowing Alzheimer disease progression and prolonging therapy benefits after plaque clearance.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 24, 2024.

The chief executive officer and cofounder of Amprion discussed the integration process of a novel a-synuclein seed amplification assay used to distinguish seeds from Lewy bodies and glilal cytoplasmic inclusions. [WATCH TIME: 2 minutes]

The neurointensivist and assistant professor of neurology at Boston Medical Center provided insight on a 2024 paper that defined consensus entrustable professional activities for neurocritical care advanced practice providers. [WATCH TIME: 5 minutes]

Take a look at some of the most-anticipated FDA pending approvals expected in 2025 that researchers and clinicians in neurology should keep an eye out on.